US flagship location opening for Bayer Co.Lab
German drugmaker Bayer (BAYN: DE) has announced the inauguration of its new life science incubator in Kendall Square, Cambridge, Massachusetts.
The company’s Co.Lab Cambridge is designed to support cell and gene therapy (CGT) entrepreneurs with access to Bayer’s expertise, in addition to offering laboratory and office space.
"The rich ecosystem that early-stage life science entrepreneurs need to pursue potential life-changing discoveries for the future of healthcare"Friedemann Janus, acting head of business development and open innovation, Bayer Pharmaceuticals, said: “The opening of our Co.Lab Cambridge in the same location as the Bayer Research and Innovation Center will create an exceptional interdisciplinary community. Its residents will benefit from the direct vicinity of industry-leading CGT pioneers, global research, development, manufacturing, and investment know-how.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze